Serum exosomal miR‐16‐5p functions as a tumor inhibitor and a new biomarker for PD‐L1 inhibitor‐dependent immunotherapy in lung adenocarcinoma by regulating PD‐L1 expression

OBJECTIVES: We aimed at investigating whether serum exosomal miR‐16‐5p could be utilized as an immunotherapy biomarker in lung adenocarcinoma (LUAD) patients administered by programmed cell death ligand‐1 (PD‐L1) inhibitors, and to evaluate its functions in LUAD progression. METHODS: Sixty LUAD suff...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hua‐Lin, Luo, Yi‐Ping, Lin, Mu‐Wen, Peng, Xiao‐Xia, Liu, Mei‐Liang, Wang, Yong‐Cun, Li, Shu‐Jun, Yang, Dong‐Hong, Yang, Zhi‐Xiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249988/
https://www.ncbi.nlm.nih.gov/pubmed/35347894
http://dx.doi.org/10.1002/cam4.4638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249988/
https://www.ncbi.nlm.nih.gov/pubmed/35347894
http://dx.doi.org/10.1002/cam4.4638

Ejemplares similares